Five things for pharma marketers to know: Friday, April 17, 2020

Gilead’s remdesivir has shown early promise treating COVID-19 patients. Patients involved in the clinical trial have shown rapid recoveries in fever and respiratory symptoms and nearly all patients in the trial were discharged in less than a week. (STAT)

Abbott’s rapid COVID-19 test may produce false negative results. The test, which was touted by President Trump, can give results in 13 minutes. The false results may be driven by the samples collected from patients and Abbott said it has issued new guidelines for how samples are collected. (STAT)

GE and Ford will produce 50,000 ventilators for the U.S. government. The two companies signed a $336 million contract to produce ventilators. They expect all of the ventilators to be finished by July 13. (CNBC)

Anti-anxiety medication prescriptions jumped 34% due to coronavirus pandemic. Prescriptions for insomnia medication increased 14.8%, and antidepressants jumped 18.6%, according to a report from Express Scripts tracking prescription data from January 1 to March 15. (MarketWatch)

Biogen has created a coronavirus biobank. Some company employees who were infected with COVID-19 have contributed blood samples and other data to the biobank. About 100 Biogen employees contracted the illness after a leadership meeting at the company’s headquarters in March. (BioPharma Dive)

The post Five things for pharma marketers to know: Friday, April 17, 2020 appeared first on MM&M – Medical Marketing and Media.

Source link

A pharma graduate turned into a content writer. Her passion towards writing and enthusiasm towards marketing trends paved a path for her to become a writer. She Has prior work experience as a content writer for digital marketing agencies and Healthcare clinics.

more recommended stories